ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1944

Expression of Human Leukocyte Antigen-G in Polymyositis or Dermatomyositis

Xiaolan Tian1, Xiaoming Shu2, Xin Lu1, Qinglin Peng3 and Guochun Wang4, 1Department of rheumatology, China-Japan Friendship Hospital, Beijing, China, 2Rheumatology, China-Japan Friendship Hospital, Beijing, China, 3Department of Rheumatology,, China-Japan Friendship Hospital, Beijing, China, 4Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Human leukocyte antigens (HLA) and polymyositis/dermatomyositis (PM/DM)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Genetics, Autoantibodies and other Molecular Aspects of Idiopathic Inflammatory Myopathies and Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Human leukocyte antigen-G is a non-classical MHC–I molecule that may be involved in the pathogenesis of autoimmune diseases, but the significance of HLA-G in polymyositis/dermatomyositis (PM/DM) remains to be determined. The aim of this study was to determine HLA-G expression in patients with PM/DM.

Methods: Consecutive cryosections of muscle biopsies obtained from 30 PM/DM patients(22 DM, 8 PM)and 8 healthy controls were detected by immunohistochemical analysis. Serum soluble HLA-G (sHLA-G) levels of 96 patients (26 PM, 70 DM) and 35 matched healthy controls were measured by ELISA. The relationship between sHLA-G levels and clinical or laboratory variables in PM/DM patients was analyzed.

Results:  HLA-G had a higher expression in 18 of 30 cases of PM/DM (60%) than that in 0 of 8 healthy controls (P =0.000). Serum level of sHLA-G in PM/DM patients were significantly higher than healthy controls [(43.96±70.20)U/ml vs (4.22±5.13)U/ml, P=0.000]. Importantly, serum sHLA-G levels in non-treated PM/DM patients(75.75±99.07 U/ml)were significantly higher than that in treated patients(33.94±51.97)U/ml, P=0.021]. Spearman rank correlation analysis showed serum sHLA-G levels were negatively correlated with CD3+Tcells(r=-0.233, P=0.047)and CD4+Tcells (r=-0.287, P=0.015) in peripheral blood in patients with PM/DM.

Conclusion: HLA-G was found to be highly expressed in muscle tissues and sera from patients with PM/DM. Serum sHLA-G is increased in PM/DM patients and is associated with lower level of CD3+T cells and CD4+T cells. These data support the notion that HLA-G overexpression has a role in the progression of PM/DM through T cells.


Disclosure:

X. Tian,
None;

X. Shu,
None;

X. Lu,
None;

Q. Peng,
None;

G. Wang,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-of-human-leukocyte-antigen-g-in-polymyositis-or-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology